CTIS2022-501190-39-01招募中1 期
OMS906-PNH-001
Omeros Ireland Limited0 个研究点目标入组 14 人开始时间: 2022年8月3日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.InfertilityCTIS2023-507066-91-00Merck Healthcare KGaA14
招募中
1 期
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial CancerMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104CTIS2024-511744-27-00Cullinan Mica Corp.500
进行中（未招募）
1 期
Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s DiseaseMedDRA version: 21.1Level: LLTClassification code: 10013113Term: Disease Parkinson's Class: 10029205Parkinson's DiseaseCTIS2023-503203-29-00odthera Limited14
进行中（未招募）
1 期
A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy ParticipantsCTIS2024-512841-17-00Merck Healthcare KGaA40
招募中
1 期
Clinical study to evaluate the safety and tolerability of SPVN06 (novel gene therapy) in a subset of patients with rod cone dystrophy (RCD).CTIS2022-501250-12-01Sparingvision33